OTCPK:PXMB.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Central America, Asia, and Oceania. More Details


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Paxman's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PXMB.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

PXMB.F

-3.3%

US Medical Equipment

-3.3%

US Market


1 Year Return

n/a

PXMB.F

13.7%

US Medical Equipment

10.9%

US Market

Return vs Industry: Insufficient data to determine how PXMB.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how PXMB.F performed against the US Market.


Shareholder returns

PXMB.FIndustryMarket
7 Day0%-3.3%-3.3%
30 Day0%-2.5%-5.7%
90 Dayn/a12.2%8.2%
1 Yearn/a14.7%13.7%13.4%10.9%
3 Yearn/a69.0%64.7%34.9%25.9%
5 Yearn/a140.9%122.6%84.6%63.8%

Price Volatility Vs. Market

How volatile is Paxman's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Paxman undervalued compared to its fair value and its price relative to the market?

21.07x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PXMB.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PXMB.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PXMB.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: PXMB.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PXMB.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PXMB.F is overvalued based on its PB Ratio (21.1x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Paxman forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paxman has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of PXMB.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Paxman's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Paxman performed over the past 5 years?

79.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: PXMB.F is currently unprofitable.

Growing Profit Margin: PXMB.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PXMB.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PXMB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PXMB.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: PXMB.F has a negative Return on Equity (-3.85%), as it is currently unprofitable.


Next Steps

Financial Health

How is Paxman's financial position?


Financial Position Analysis

Short Term Liabilities: PXMB.F's short term assets (SEK33.5M) do not cover its short term liabilities (SEK39.8M).

Long Term Liabilities: PXMB.F's short term assets (SEK33.5M) exceed its long term liabilities (SEK21.9M).


Debt to Equity History and Analysis

Debt Level: PXMB.F's debt to equity ratio (174.3%) is considered high.

Reducing Debt: Insufficient data to determine if PXMB.F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PXMB.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PXMB.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.1% each year.


Next Steps

Dividend

What is Paxman current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PXMB.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PXMB.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PXMB.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PXMB.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PXMB.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average board tenure


CEO

Richard Paxman (37 yo)

7.67yrs

Tenure

kr1,643,000

Compensation

Mr. Richard Paxman has been the Chief Executive Officer of Paxman AB (publ) since 2013 and has been its Director since February 10, 2017. Mr. Paxman has extensive experience in global market development in ...


CEO Compensation Analysis

Compensation vs Market: Richard's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD606.89K).

Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Richard Paxman
CEO & Director7.67yrskr1.64m8%
SEK 4.6m
Per-Anders Johansson
Independent Chairman of the Board3.75yrskr100.00k0.62%
SEK 357.0k
Robert Kelly
Independent Director3.67yrskr50.00kno data
Maria Bech
Independent Director3.67yrskr50.00k0.054%
SEK 31.1k
Björn Littorin
Independent Director3.75yrskr50.00k4.78%
SEK 2.7m
Glenn Paxman
Director3.67yrsno data39.15%
SEK 22.4m

3.7yrs

Average Tenure

61.5yo

Average Age

Experienced Board: PXMB.F's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Paxman AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Paxman AB (publ)
  • Ticker: PXMB.F
  • Exchange: OTCPK
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr522.008m
  • Listing Market Cap: kr57.159m
  • Shares outstanding: 16.01m
  • Website: https://www.paxman.se

Number of Employees


Location

  • Paxman AB (publ)
  • Pirgatan 13
  • Karlshamn
  • Blekinge County
  • 374 35
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PAXOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2017
PXMB.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2017

Biography

Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Centr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/25 06:15
End of Day Share Price2020/08/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.